Beam Therapeutics
BEAMBeam Therapeutics is a biotechnology company developing a proprietary base editing platform to create precision genetic medicines for serious diseases.
Earnings
Next report
Aug 4, 2026 (In 6 days)Valuation & ratios
Competitors
By market cap
By revenue growth
Profile
Beam Therapeutics is a biotechnology company developing a proprietary base editing platform to create precision genetic medicines for serious diseases. Their technology enables single-base changes in the genome without causing double-stranded DNA breaks, potentially offering a safer and more precise alternative to traditional CRISPR nuclease editing. The company integrates gene editing, diverse delivery modalities like lipid nanoparticles, and internal manufacturing to advance a broad portfolio of curative therapies.
A pioneer in base editing technology with a fully integrated platform spanning discovery, delivery, and internal cGMP manufacturing.
Questions, answered.
- What is Beam Therapeutics's market cap?
- Beam Therapeutics (BEAM) has a market capitalization of $2.6B and trades on NASDAQ.
- What is Beam Therapeutics's revenue and profitability?
- Beam Therapeutics generated $164.0M in trailing twelve-month revenue with a net loss of $417.7M, representing a net margin of -742.7%, with free cash flow of -$383.8M. These figures are based on the Q1 2026 filing.
- Who are Beam Therapeutics's competitors?
- Beam Therapeutics's key competitors include CRISPR Therapeutics, Wave Life Sciences, Vertex Pharmaceuticals, and others. These companies compete in similar markets and product categories.
- Who does Beam Therapeutics partner with?
- Beam Therapeutics's notable partners include Pfizer Inc., Apellis Pharmaceuticals, Inc., Verve Therapeutics, Inc., and others.
- Where is Beam Therapeutics headquartered?
- Beam Therapeutics is headquartered in United States of America and employs approximately 436 people. It has been publicly traded since 2020.
